Cell line · CVCL_0152
Papers220
1 to 20 of 220
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Long Noncoding RNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness, DNA Repair, and Chemoresistance in Pancreatic Cancer | IUBMB Life | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selective AUTAC-mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma. | Clin Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Differential Sensitivity to xCT-inhibition by ME1 expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Structure-based redesign enables clinical translation of CAIX-targeted theranostics in clear cell renal cell carcinoma. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microenvironmental arginine restriction sensitizes pancreatic cancers to polyunsaturated fatty acids by suppression of lipid synthesis. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Uncertainty-aware quantitative analysis of high-throughput live cell migration data. | PLoS Comput Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERO1L induces macrophage infiltration to potentiate KrasG12D and inflammation-induced pancreatic tumorigenesis via oxidative protein folding of CCL2. | Cell Biosci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. | MedComm (2020) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0152/papers